Skip to content 
Author: Dr. Kim, Medical Doctor at Aurea Care (Pen name)
A Litmus Test for Political Intelligence
Yes, this is an article about a plant-based medicine. But more than that, it is a litmus test.
A test of whether Swedish decision-makers understand what evidence is. What proportionality is. And perhaps most importantly, what consequences are.
The Dental and Pharmaceutical Benefits Agency (TLV) wants to remove reimbursement for cannabis-based extemporaneous medicines. The Stockholm Region refers to alleged “fraud.” At the same time, the patient population is growing because the treatment, for an increasing number of seriously ill individuals, works.
This is where the test lies.
Can we, in Sweden, hold two thoughts in our heads at the same time? That irregularities must be investigated and addressed, and that effective treatment should not be dismantled as a regulatory reflex? Or will we allow suspicion and symbolic value to outweigh documented patient benefit?
At its core, the question is simple. Do we want to make medical decisions based on facts, or on political convenience? And even more simply: should patient benefit or political signaling guide Swedish healthcare?
Is Medical Cannabis Legal in Sweden?
Yes.
And one could, in theory, end the discussion there.
Medical cannabis is legal in Sweden. It has been legal for a long time. Physicians are permitted to prescribe cannabis-based medicines, both registered products and extemporaneous preparations, within the framework of existing pharmaceutical legislation.
In Swedish clinical practice, the treatment is primarily used for chronic neuropathic pain, nociplastic pain (such as fibromyalgia), MS-related spasticity, and severe sleep disturbance secondary to
long-term pain.
Internationally, the evidence base continues to grow across several areas, including inflammatory bowel disease, migraine, endometriosis, palliative care, certain forms of epilepsy, and neurodegenerative disorders.
Medical cannabis is anything but a stagnant field. It is an area of rapid development, with expanding clinical experience and an evolving research base.
Patients who seek medical cannabis are not individuals who simply “want to try something alternative.” They are, as a rule, fully evaluated and treated according to standard medical protocols. They have followed treatment algorithms. They have seen orthopedic specialists. Pain specialists.
Neurologists. They have been assessed as non-operable. They have been placed on conservative management plans. They have done what the system expects them to do.
The average patient with long-standing neuropathic pain who reaches cannabis treatment has already tried paracetamol, NSAIDs, opioids, gabapentinoids, antidepressants, Z-drugs, benzodiazepines, and antiepileptics.
Often for years. Often in combination. Often with significant side effects.
Medical cannabis is typically a third- or fourth-line option, introduced when conventional therapy has been insufficient, when side effects have been unacceptable, and when the patient lives with significant functional impairment and substantially reduced quality of life.
In other words, this is not casual prescribing. It is a treatment for patients who have done everything “right” and are still in pain.
Cannabis is rarely the first step. It is often the last resort. And for many, the first one that actually works.
TLV’s “Fraud” Argument Is A Logical Collapse
TLV refers to irregularities linked to a former clinic. Let us be precise.
A physician used a workplace code and infrastructure outside the scope of his employment. This was identified and reported by the company’s management to the Economic Crime Authority and to the
Health and Social Care Inspectorate (IVO). The physician was suspended in the summer of 2022. His medical license was revoked. The clinic has been closed since then.
The system worked. The error was identified. It was reported. It was addressed.
That is how oversight is supposed to function in a rule-of-law system. Yet this single, already resolved case is now being used as justification to withdraw reimbursement for cannabis-based extemporaneous medicines for patients across Sweden.
That is not proportionate. It is not medically justified. It is not regulatorily consistent.It is collective punishment.
Moreover, IVO has reviewed the two currently operating clinics, Aurea Care and Sapphire Clinics, without finding evidence of systematic fraud or improper prescribing. There is therefore no ongoing documented systemic irregularity, no IVO criticism of current operations, and no evidence of structural overprescribing.
Despite this, TLV and Region Stockholm continue to insinuate that “fraud” is occurring.
If there is evidence, present it. If there is no evidence, stop using the word. Regulatory legitimacy rests on proportionality. When a single, properly addressed case is subsequently used as grounds for dismantling national access to a lawful treatment, that is not oversight.
It is political signaling. And political signaling is a poor tool for pharmaceutical governance.
“There Are Already Approved Medicines.” The Sativex Argument.
TLV and Region Stockholm seek to withdraw reimbursement for cannabis-based extemporaneous preparations, that is, individually compounded oil-based medicines marketed under the names Dronabinol (THC) and Cannabidiol (CBD).
These are pharmacy-prepared medicines, prescribed by licensed physicians, within the framework of Swedish pharmaceutical law. The argument advanced is that a registered cannabis-based medicine already exists on the market: Sativex.
Let us clarify what that actually means.
Sativex is approved for MS-related spasticity. It is not approved for chronic neuropathic pain. Not for fibromyalgia. Not for the majority of indications where extemporaneous preparations are currently used.
Referring to Sativex as a general alternative for long-term pain therefore conflates distinct indications. It is not the same patient population. It is not the same clinical problem. And even if one sets the indication issue aside, the practical question remains: does it function as a substitute?
Sativex has a fixed THC/CBD ratio. The proportion of THC to CBD cannot be adjusted individually. The patient therefore receives a predetermined cannabinoid profile, regardless of age, tolerance, symptom pattern, comorbidity, or sensitivity to THC.
In practice, this means limited ability to optimize treatment effect, reduced ability to minimize side effects, and no real flexibility between different patient profiles.
Cannabinoid therapy is fundamentally individualized medicine. It relies on titration, gradually adjusting dose and THC/CBD ratio to identify the lowest effective level with tolerable side effects. That flexibility is precisely what extemporaneous preparations allow.
It is precisely what Sativex does not.
In addition, Sativex is administered as an alcohol-based oromucosal spray. Clinical experience frequently shows oral irritation, burning sensations in the mouth, ulceration, and persistent unpleasant taste.
These are not trivial complaints. For some patients, they become treatment-limiting.
To claim that Sativex “is sufficient” as a replacement for extemporaneous preparations is pharmacologically simplistic and clinically detached from reality.
It is akin to arguing that insulin “is sufficient” without the ability to adjust the dose.
It is not a serious argument. And it is neither medically nor ethically defensible to use it as the basis for restricting access to individualized treatment.
What Happens If Reimbursement Is Withdrawn?
If coverage under the national high-cost protection scheme is removed, four serious consequences follow.
One. Inequality increases.
Access to treatment will become dependent on personal financial capacity. Only well-resourced patients will be able to afford continued therapy. Pain management becomes a class issue.
Two. Opioid prescribing increases.
When cannabis is removed from the therapeutic arsenal, opioids often remain the only available option. International data demonstrate a negative correlation between access to medical cannabis and opioid consumption. Remove one, and pressure on the other increases.
Three. Long-term sick leave increases.
Many patients return to work because extemporaneous preparations provide functional improvement. If treatment becomes financially inaccessible, the cost does not disappear. It merely shifts from the pharmaceutical budget to the social insurance system.
Four. The illicit market expands.
Patients who experience documented treatment benefit do not stop being in pain when reimbursement disappears. They simply stop purchasing through regulated pharmacies. To believe otherwise is regulatorily naïve.
This Is Bigger Than Cannabis
The real question extends far beyond a single class of medicine.
Should Sweden be a country where patients who do not respond to conventional treatment are granted access to alternative therapies within the bounds of the law? Or a country where political apprehension overrides clinical reality?
There are currently no confirmed signs of systematic misconduct among the clinics in operation. There are patients with documented improvements in function and return to work. There are licensed physicians practicing within the framework of existing legislation.
To withdraw reimbursement under these circumstances sends a troubling signal: that ideology outweighs demonstrated patient benefit. That regulatory anxiety takes precedence over medical utility. That administrative discomfort is given priority over clinical outcomes.
It sets a dangerous precedent.
If a lawful treatment, used within the regulatory framework and without confirmed systemic wrongdoing, can be dismantled on the basis of optics rather than data, then the boundary for how medical decisions are made in Sweden has shifted.
That shift extends far beyond cannabis.
Final Words to Decision-Makers
This is a litmus test.
You can choose to stand up for evidence-based, proportionate, and individualized care. Or you can choose symbolic politics and regulatory overreaction.
If reimbursement is withdrawn, measurable consequences will follow. More opioid prescriptions. More long-term sick leave. More patients in financial distress. More purchases outside the regulated pharmacy system.
All of this despite the treatment being legal. Despite it being used within the regulatory framework. Despite the fact that for some patients it represents the difference between functional capacity and permanent disability.
The question is whether Sweden can afford to dismantle a therapy that works for patients who have already exhausted their alternatives.
The decision rests with you.
But the consequences will be borne by those with the least margin, and the most to lose.